topstockalerts
Nov 10, 12:47 AM
Veradermics reported positive 12-month results from Part B of its Phase 2/3 '302' trial evaluating VDPHL01, an oral treatment for mild-to-moderate male pattern hair loss. The 519-patient randomized, double-blind, placebo-controlled study showed a 43.9 hairs/cm² increase in non-vellus hair count with twice-daily dosing, compared with 29.7 hairs/cm² with once-daily treatment. Results demonstrated continued hair growth with twice-daily dosing and maintenance of gains with once-daily treatment. VDPHL01 remained generally well tolerated, with no new safety signals.
Following the results, Leerink Partners raised its price target on Veradermics to
$150 from
$135. Combined with previously positive topline results from Part A of Study '302' and Phase 3 Study '304', the findings strengthen the potential for VDPHL01 to become the first FDA-approved oral pill for androgenetic alopecia in nearly 30 years.
$MANE
